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A B S T R A C T
Recently, haploidentical transplantation (haplo) using post-transplant cyclophosphamide (PTCy) has been
reported to give very encouraging results in patients with hematological malignancies. Patients who have no
HLA-matched donor currently have the choice between a mismatched unrelated donor, an unrelated cord blood
(CB) donor, and a haploidentical related donor. The aim of our study is to compare the outcome of patients with
myelodysplastic syndrome (MDS) who have been transplanted from a haploidentical donor using PTCy, an HLA-
mismatched unrelated donor (marrow or peripheral blood stem cells), or an unrelated mismatched CB donor. A
total of 833 MDS patients from the European Group for Blood and Marrow Transplantation (EBMT) registry, trans-
planted between 2011 and 2016, were identified. The potential benefit of haplo was compared with mismatched
unrelated and CB donors in an adjusted and weighted model taking into account potential confounders and other
prognostic variables. Haplo was at lower risk of acute graft-versus-host disease (GVHD) than mismatched unre-
lated donor (P = .010) but at similar risk than CB. Progression-free survival was better after haplo (versus
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mismatched unrelated, P = .056; versus CB, P = .003) and overall survival tended to be superior after haplo (versus
mismatched unrelated, P = .082; versus CB, P = .002). Nonrelapse mortality was not significantly different between
haplo and mismatched unrelated donors. Relapse risk was not influenced by the type of donor. In conclusion,
patients with MDS from the EBMT registry receiving hematopoietic stem cell transplantation from a haplo donor
have significantly better outcome than those receiving hematopoietic stem cell transplantation from a CB donor
and at least similar or better outcome than with a mismatched unrelated donor. Prospective studies comparing
the type of donors will be needed to confirm this assumption.
© 2018 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation remains
the only curative treatment in patients with myelodysplastic
syndrome (MDS). The reduction in transplant-related mortality
in recent years has expanded the applicability of transplant to
older patients and those with comorbidities. This is particularly
relevant for patients with MDS who have a median age at diag-
nosis of 72 years. The introduction of reduced-intensity condi-
tioning (RIC) regimens and the improvement in donor
availability has further contributed to an increase transplant
numbers globally. Lack of donor availability is less a significant
problem given improvements in HLA typing methodology
allowing better choices among unrelated donors, the develop-
ment of cord blood banking, and finally the recent impressive
improvements in haploidentical transplantation [18]. Indeed,
patients lacking an HLA-matched donor could benefit from a
mismatched unrelated donor (MisUD), haploidentical donor
(haplo), or unrelated cord blood (CB) donor. Lee et al. [9]
recently gave an European Group for Blood and Marrow Trans-
plantation (EBMT) position regarding the place of haplo in
patients with acute leukemia, stating that it is a valid option for
patients without an HLA-matched donor or in patients needed
an urgent transplant but fewer data are available in MDS. The
EBMT group has previously reported that haplo performed
before 2014 in MDS patients was complicated by a relatively
high nonrelapse mortality (NRM); however, patients who
received post-transplant cyclophosphamide (PTCy) as graft-ver-
sus-host disease (GVHD) prophylaxis had a better outcomes
[10]. Given these significant improvements the question arises
whether haploidentical transplantation using PTCy may be a
better option for patients with MDS when fully matched HLA
donors are unavailable. Herein we report a recent EBMT analysis
comparing transplant outcomes among haplo with PTCy,
MisUD, and CB.
METHODS
Patients with a primary diagnosis of MDS transplanted between 2011 and
2016 and registered in the European ProMise database were included if they had
information regarding the type of donor: unrelated CB, MisUD (1 HLA mismatch
of 10), or mismatched HLA-related donor (at least 2 mismatches). All time-to-
event outcomes were counted from the date of transplant to the date of event or
date of last follow-up. Grade II to IV acute GVHD was analyzed as a binary vari-
able, as information was available for all patients with follow-up shorter than 3
months. NRM was considered as death by any cause occurring before disease
relapse/progression. Death and second transplant were considered as a compet-
ing event for chronic GVHD. NRM and relapse/progression were considered to be
mutually competing risks. The primary objective was to compare outcomes
between the 3 donor groups, namely mismatched related donor (haplo), MisUD,
and unrelated CB. To account for potential confounding, several strategies were
used. First we used regression adjustment, by adjusting the analyses on potential
confounders using Cox proportional hazards (overall survival [OS], progression-
free survival [PFS]), proportional cause-specific hazards (competing risk out-
comes), and logistic (grade II to IV acute GVHD) regression models. Variables
used for adjustment were period of transplantation, age, patient sex, disease clas-
sification, time to transplant, blast count at transplantation, status at transplant,
female donor to male recipient, cytomegalovirus recipient/donor matching, and
conditioning regimen. Then we used inverse probability of treatment weighting
[11,12]. This approach aims at reconstructing by weighting pseudopopulations
where patients in the different groups have similar characteristics (pipeline is
available in the Supplementary Methods). Inverse probability weights were
obtained by modeling the group as a response variable in a multinomial model
with the same variables as those used for regression adjustment as predictors. To
avoid unstable results due to extreme weights, weights were trimmed at their
first and 99th percentile (ie, the lowest and highest 1% weights were set equal to
the first and 99th percentile, respectively). Last regression adjustment and
inverse probability of treatment weighting were combined. For logistic and Cox
models in the weighted sample, we used a robust variance estimator. Adjusted
survival curves and cumulative incidence curves were obtained using the weight-
ing approach [13]. The proportional hazards assumption was checked by exami-
nation of Schoenfeld residuals and Grambsch and Therneau's lack-of-fit test [14].
Missing data were handled through multiple imputations by chained equations
methods [15,16]. Because International Prognostic Scoring System (IPSS) score
and cytogenetics were missing for most patients, they were neither imputed nor
used for imputation. With other predictors, 19% of patients had missing potential
prognostic factors, so that 20 independent imputed datasets were generated and
analyzed separately [17]. Variables used for multiple imputations were factors
used for adjustment. Estimates of model parameters and discrimination indexes
were then pooled over the imputations according to Rubin's rule [15]. All tests
were 2-sided. Analyses were performed using the R statistical software version
3.4.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient and Transplant Characteristics
A total of 833 patients undergoing a first hematopoietic stem
cell transplantation for MDS between January 2011 and January
2016 were included in the study. Median follow-up was 30
(interquartile range, 18 to 47) months. Follow-up was shorter in
the haplo group (median 24 months) than in the CB (median 37
months) and MisUD (median 33 months) groups (P = .002). Main
characteristics of patients and transplant are given in Table 1.
Characteristics did not differ according to donor type for patient
and donor sex, disease classification, median time from diagnosis
to transplant, and cytogenetics. Haplo transplanted patients were
older (61 years of age), have been transplanted more recently
(71% in 2014 to 2016), were less frequently in complete remis-
sion (CR) at time of transplant (29%). MisUD transplanted patients
were characterized by a higher proportion of CR at time of trans-
plant (38%), the more frequent use of peripheral blood as source
of stem cells as compared with haplo (90% versus 54%), a high
proportion of RIC (70%), and in vivo T cell depletion (86%).
Patients transplanted from unrelated cord blood received RIC in a
similar proportion to MisUD (69%) but more frequently received
total body irradiation (TBI) (24%) and were younger.
Transplant Outcome
During follow-up, 447 patients died. Relapse was the cause of
death for approximately one third of patients (33% in MisUD, 34%
in haplo, and 31% in CB). Among nonrelapse causes of mortality,
infection was the most frequent for the 3 groups: 45% for MisUD,
68% for haplo, and 56% for CB (among known causes of death,
missing in 20 MisUD, 21 haplo, and 3 CB) followed by GVHD:
41%, 30%, and 25% for MisUD, haplo, and CB, respectively.
Weighted estimations for probability and incidences are
reported in Table 2. Briefly, the probability of neutrophil
engraftment was lower using CB (76% versus 84%) and grade
II to IV acute GVHD was lower with haplo (23% versus 32%).
Three-year adjusted cumulative incidence of chronic GVHD
was higher using MisUD (39%) or haplo (36%) than using CB
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(29%). Three-year adjusted OS was 47%, 38%, and 31% with
haplo, MisUD, and CB, respectively, while 3-year adjusted PFS
was 43%, 33%, and 29%, respectively (Figure 1). Three-year
NRM and 3-year relapse incidence were 36%, 40%, and 48% and
21%, 27%, and 23%, with haplo, MisUD, and CB, respectively
(Figure 1). Comparison significance (P value) of haplo versus
MisUD or CB of the weighted model is given in Table 3. Of
note, in haplo, the use of marrow instead of peripheral blood
(PB) was not a significant protector (hazard ratio [HR], 1.56;
95% confidence interval, .95 to 2.56; P = .077) while the source
of stem cells had no impact on chronic GVHD incidence (HR,
1.08; 95% confidence interval, .66 to 1.76; P = .75).
Effect of the Type of Donor
To test the potential advantage of 1 type of donor over
the others, 3 kinds of analyses were done: weighted; adjusted
Cox analysis on period of transplantation, age, patient sex,
disease classification, time to transplant, blast count at trans-
plantation, status at transplant, female donor to male recipient,
cytomegalovirus recipient/donor matching, and conditioning
regimen; and a combined adjusted and weighted analysis. The
complete adjusted analysis is available in Supplementary
Table S1. The effect of the type of donor is shown in Table 3.
Looking at the 3 models, the engraftment was generally better
with haplo as compared with CB (HR between .55 and .59, P
value between .057 and .094) but it was worse with haplo as
compared with MisUD (HR between 1.47 to 1.67, P value
between .066 and .14) without reaching significance. Grade II
to IV acute GVHD was significantly reduced in haplo as com-
pared with MisUD (HR between 1.68 and 1.79, P value between
.011 and .006), but not significantly different as compared with
CB even if there was a trend (HR between 1.52 and 1.56, P
value between .071 and .10). Chronic GVHDwas not influenced
by the type of donor. Relapse risk was not influence by the type
of donor. All 3 models were in favor of a significantly better
outcome for NRM, PFS, and OS with haplo as compared with
CB (P value always .01 for the 3 models and 3 endpoints)
(Table 3). When haplo was compared with MisUD, NRM was
not significantly reduced (HR between 1.18 and 1.29, P value
between .096 and .31) while there was a trend to a better PFS
(P value between .034 and .056) and OS (P value between
.027 and .082) with haplo.
Discussion
This study from the EBMT registry compared outcomes of
patients who received transplant from a haploidentical donor,
a MisUD or an unrelated CB donor in patients with MDS. The
aim was to determine the best alternate donor in patients
without a fully HLA-matched donor. Given the inherent limita-
tions of the retrospective studies, we used 2 different methods
to correct clinical disparities when testing the impact of donor
type. In details, we used both regression adjustment and
inverse probability weighting [18,19]. Formally regression
adjustment and inverse probability weighting estimate a dif-
ferent treatment effect (conditional versus marginal) and rely
on different assumption. Using several approaches is often
used to strengthen the analysis of observational data as we
and other have previously reported [2022]. There remained
differences in patients and transplant characteristics inherent
to the transplant procedures and linked to donor type, for
example, the use of post-transplant cyclophosphamide in
haplo, the use of marrow or peripheral blood stem cells in
haplo or MisUD, or the frequent use of TBI, which characterized
the CB procedure. This could be explained by the different
“packages,” related with each procedure and type of graft (ie,
PCT used with haplo, peripheral blood and in vivo T cell deple-
tion used with MisUD, a TBI-based regimen with CB). Adjusted
models take into account potential other risk factors, especially
if they are unequally balanced between groups. The weighted
model is done to correct differences between populations in
each group and to create populations which are comparable.
Hence adjusted and weighted models are probably most
reflective of the real effect of type of donor.
In our study, NRM was the highest after CB consistent with
other studies in acute myelogenous leukemia [4,23] and previ-
ous EBMT report comparing CB with PB [24]. Of note, NRMwas
relatively high after all types of HLA-mismatched transplant.
While NRM is usually reported at <20% after haplo [5,2527],
Table 1
Characteristics of the Patients
Haplo MisUD CB P Value
Patient number 222 443 168
Transplant period
2011-2013 64 (29) 259 (59) 120 (71)
2014-2016 158 (71) 184 (41) 48 (29) <.0001
Sex
Female 97 (44) 166 (37) 71 (42)
Male 125 (56) 277 (62) 97 (58) .25
Age at transplant, yr 61 (51-66) 59 (52-65) 57 (45-64) .004
Disease classification
RA/RARS/del5q 11 (5) 20 (4.5) 7 (4)
RCMD 25 (11) 52 (12) 7 (4)
RAEB 97 (44) 186 (42) 78 (46)
Secondary AML 74 (33) 161 (36) 64 (38)
Unclassifiable/other 15 (7) 24 (5.5) 12 (7) .30
Time from diagnosis to
transplant, mo
13 (8-26) 11 (7-21) 11 (6-22) .12
Marrow blasts
<5% 97 (45) 225 (53) 91 (56)
5% 119 (55) 202 (47) 70 (43) .061
Missing 6 16 7
Status at transplant
Untreated 33 (16) 91 (22) 23 (14)
CR 60 (29) 159 (38) 78 (49)
Non CR 115 (55) 170 (40.5) 59 (37)
Missing 14 23 8 .0002
Cytogenetics*
Good 56 (54) 106 (48) 35 (40
Intermediate 28 (27) 56 (25.5) 33 (38)
Poor 20 (19) 58 (26.5) 20 (23)
Missing 118 223 80 .15
Donor/recipient sex match
Female/male 37 (17) 91 (20.5) 34 (20)
Other 185 (83) 352 (79.5) 134 (80) .48
Donor/recipient
cytomegalovirus match
Negative/negative 36 (17) 102 (24)
Positive/negative 9 (4) 39 (9)
Negative/positive 41 (24) 133 (31)
Positive/positive 118 (55) 152 (36)
Missing 8 17
Stem cell source <.0001
Marrow 101 (45.5) 43 (10)
PB 121 (54.5) 400 (90)
Regimen
RIC 123 (55.5) 308 (70) 116 (69)
Myeloablative 99 (45) 134 (30) 52 (31) .0009
Missing 0 1 0
TBI 4 Gy 9 (4) 19 (4) 40 (24) <.0001
In vivo T cell depletion 9 (4) 381 (86) 74 (44) <.0001
Missing 0 11 3
Post-transplant
cyclophosphamide
222 (100) 28 (6.5) 5 (3)
Missing 0 11 3 <.0001
Values are n (%) or median (interquartile range).
AML indicates acute myelogenous leukemia; RA, refractory anemia; RARS,
refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with
multilineage cytopenia; RAEB, refractory anemia with excess blasts.
* The cytogenetics group is defined as described in IPSS [38].
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it was 36% in the current study, which was slightly lower with
the previous MDS EBMT report on haplo (41%) [10]. The use of
PTCy instead of ex vivo T cell depletion reduces the immuno-
logical defect; however, infections remained the first cause of
death in haplo using PTCy, as it is after CB transplant. Regard-
ing the role of source of stem cells in haplo, NRM was not sig-
nificantly higher using PB, even if there was a trend. The
reason why MDS patients are more susceptible to die from
NRM than patients with other diseases remains unclear but
hypotheses could include the relatively older age of this group,
potential treatment for previous malignancies, which make
patients more sensitive to toxicity, and possibly more comor-
bidities. GVHD and death related to GVHD were more frequent
after MisUD in this series. Taken with caution the registry data
Table 2
Probabilities and Incidence for Outcome
Outcome at 3 yr Haplo (95% CI) (%) MisUD PB or marrow (%) Unrelated CB (%)
Engraftment 84 (79-89) 90 (87-93) 76 (69-82)
Grade II-IV acute GVHD 23 (17-28) 35 (31-40) 32 (25-40)
Chronic GVHD 36 (28-44) 39 (33-44) 29 (21-37)
OS 47 (40-56) 38 (33-43) 31 (25-40)
PFS 43 (36-51) 33 (28-38) 29 (22-37)
NRM 36 (27-44) 40 (35-45) 48 (39-57)
Relapse 21 (15-28) 27 (22-32) 23 (16-31)
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Figure 1. Outcome of patients according to the type of donor: (A) OS, (B) PFS, (C) NRM, and (D) relapse incidences. Potential significance between haplo and MisUD or
haplo and CB are given in Table 3.
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which do not always distinguish primary or secondary cause of
death (ie; GVHD versus infection), haplo appears to be fol-
lowed by a higher rate of mortality due to infection, while
MisUD was followed by higher rate of mortality due to GVHD
leading to similar NRM haplo and MisUD.
Alternatively, it is uncertain that patients have received opti-
mal GVHD prophylaxis. While prospective studies have
reported the benefit of in vivo T cell depletion [2831], this was
not consistently used in all MisUD patients potentially contrib-
uting to higher rates of GVHD. Additionally the use of PTCy in
the setting of unrelated transplant is challenging with interest-
ing results reported so far [32,33]. In our study only 6.5% of
patients in the MisUD received PTCy preventing any conclu-
sions. For inferior outcomes with CB, similar observations can
be done. Indeed, in a recent joint study from EBMT-EUROCORD,
RIC was followed by the best outcome however 31% of patients
in this cohort received a myeloablative approach [34]. In addi-
tion, the benefit of in vivo T cell depletion in CB transplant is
highly debated however 44% of patients received it. Further-
more, high number of nucleated cells at CB collection is an
important risk factor for outcome, but CB patients were all
included regardless of the number of cells due to insufficient
data on cell number. Other characteristics known to influence
success in mismatched transplantation such as presence of
donor directed HLA antibodies, CD34 count, and potency met-
rics such as CFU assay results were also not available. Results in
patients transplanted from CB may have been better if we had
excluded those with poor graft characteristics.
Given the possibility that haplo donors could have been
selected based on a strategy believed to be better (the use of
PTCy) but MisUD and CB have not been selected on donor
availability, and comparison between groups should be inter-
preted with caution.
It is important to note that as in all studies, the current
analysis reflects past results (2011 to 2016) and we cannot
extrapolate to future years because 1 or several procedures
and management strategies continue to improve. In 2017, we
reported quite disappointing OS (38%) after haplo using PTCy
performed previously (2006 to 2014), which has now
increased to 47% (2011 to 2016), even if NRM remains rela-
tively high (36%) [10]. The increased numbers of haplo trans-
plant and substantial improvement in supportive care have
probably contributed to improved expertise of centers trans-
planting into a decrease in mortality [1].
Regarding relapse risk, it is noteworthy that there was no dif-
ference between the 3 donor types. While it has been supposed
that relapse risk may be increased after haplo, we failed to find it
in this study confirming that graft-versus-MDS effects may be as
strong as after HLA-MisUD. Relapse risk excess in haplo was ini-
tially reported after nonmyeloablative protocols using marrow as
source of stem cells but not been confirmed recently and is not
reported in more recent series [7,35,36]. One explanation may be
that even if haplo is followed by lower risk of acute GVHD, the
risk of chronic GVHD is as high as after unrelated donor trans-
plant, possibly maintaining the graft-versus-MDS effect. The
source of stem cells in haplo or MisUD might have an impact on
chronic GVHD and relapse risk. In this study, the vast majority of
MisUD transplant was PB, which prevented any supplemental
statistical analysis. Regarding haplo, it has previously been dem-
onstrated by the EBMT in MDS patients that the source of stem
cells did not matter for outcome (OS, PFS, NRM, chronic GVHD)
[6]. Two recent registry studies have also reported in patients
with mixed malignancies that outcomes appear similar using PB
or marrow [36,37].
In conclusion, the results of this large EBMT analysis show
that the outcome from haplo using PTCy in MDS is a valid
Table 3
Effect of the Type of Donor on Outcome
Adjusted Weighted Adjusted and weighted
OR/HR (95% CI) P Value OR/HR (95% CI) P Value OR/HR (95% CI) P Value
Engraftment
Haplo 1 1 1
MisUD 1.47 (.88-2.46) .14 1.67 (.97-2.88) .066 1.60 (.93-2.76) .091
CB .57 (.32-1.02) .060 .59 (.32-1.09) .094 .55 (.30-1.02) .057
Grade II-IV acute GVHD
Haplo 1 1 1
MisUD 1.68 (1.13-2.49) .011 1.83 (1.19-2.81) .006 1.79 (1.15-2.78) .010
CB 1.52 (.93-2.49) .092 1.62 (.96-2.74) .071 1.56 (.91-2.66) .10
Chronic GVHD
Haplo 1 1 1
MisUD 1.17 (.85-1.60) .35 1.15 (.83-1.61) .39 1.11 (.78-1.59) .57
CB 1.07 (.72-1.61) .74 1.00 (.65-1.54) .99 .95 (.60-1.50) .82
Relapse/progression
Haplo 1 1 1
MisUD 1.27 (.88-1.83) .21 1.35 (.91-2.02) .14 1.36 (.90-2.05) .14
CB 1.25 (.78-2.01) .35 1.37 (.83-2.25) .22 1.38 (.83-2.31) .21
NRM
Haplo 1 1 1
MisUD 1.29 (.96-1.74) .096 1.18 (.86-1.63) .31 1.23(.88-1.72) .22
CB 1.68 (1.17-2.41) .005 1.66 (1.13-2.45) .010 1.76 (1.16-2.65) .007
PFS
Haplo 1 1 1
MisUD 1.29 (1.02-1.62) .034 1.24 (.97-1.60) .090 1.29 (.99-1.67) .056
CB 1.51 (1.14-2.02) .005 1.56 (1.14-2.13) .005 1.64 (1.18-2.27) .003
OS
Haplo 1 1 1
MisUD 1.32 (1.03-1.69) .027 1.22 (.94-1.59) .13 1.27 (.97-1.67) .082
CB 1.65 (1.23-2.23) .001 1.61 (1.17-2.22) .003 1.73 (1.23-2.42) .002
Haplo is the reference in this analysis.
OR indicates odds ratio.
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option, possibly better than CB. As previously suggested in the
setting of acute leukemia, in patients without an HLA-matched
donor, haplo should be considered [9]. Furthermore, the cost
effectiveness may in in favor haplo over an unrelated trans-
plant. Prospective studies comparing the type of donor (haplo
versus MisUD), especially using the same platform (PTCy) are
required answer to this dilemma.
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